Skip to content 
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. more
| Time Frame | AMRX | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 3.33% | 0.72% | -1.31% |
| 1-Month Return | 13.95% | 1.27% | 0.78% |
| 3-Month Return | 31.29% | 3.13% | 3.46% |
| 6-Month Return | 64.04% | 15.81% | 6.19% |
| 1-Year Return | 94.99% | 8.89% | 11.68% |
| 3-Year Return | 554.74% | 20.79% | 71.21% |
| 5-Year Return | 169.8% | 35.89% | 74.81% |
| 10-Year Return | -56.59% | 138.44% | 256.59% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 1.99B | 2.09B | 2.21B | 2.39B | 2.79B | [{"date":"2020-12-31","value":71.32,"profit":true},{"date":"2021-12-31","value":74.94,"profit":true},{"date":"2022-12-31","value":79.18,"profit":true},{"date":"2023-12-31","value":85.67,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Cost of Revenue | 1.36B | 1.32B | 1.42B | 1.53B | 1.77B | [{"date":"2020-12-31","value":76.92,"profit":true},{"date":"2021-12-31","value":74.69,"profit":true},{"date":"2022-12-31","value":80.11,"profit":true},{"date":"2023-12-31","value":86.25,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Gross Profit | 628.39M | 768.97M | 791.46M | 863.87M | 1.02B | [{"date":"2020-12-31","value":61.58,"profit":true},{"date":"2021-12-31","value":75.36,"profit":true},{"date":"2022-12-31","value":77.56,"profit":true},{"date":"2023-12-31","value":84.66,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Gross Margin | 31.54% | 36.73% | 35.78% | 36.09% | 36.52% | [{"date":"2020-12-31","value":85.87,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.41,"profit":true},{"date":"2023-12-31","value":98.26,"profit":true},{"date":"2024-12-31","value":99.44,"profit":true}] |
| Operating Expenses | 537.24M | 616.26M | 886.39M | 659.50M | 771.11M | [{"date":"2020-12-31","value":60.61,"profit":true},{"date":"2021-12-31","value":69.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":74.4,"profit":true},{"date":"2024-12-31","value":86.99,"profit":true}] |
| Operating Income | 91.16M | 152.72M | (94.93M) | 204.37M | 249.33M | [{"date":"2020-12-31","value":36.56,"profit":true},{"date":"2021-12-31","value":61.25,"profit":true},{"date":"2022-12-31","value":-38.07,"profit":false},{"date":"2023-12-31","value":81.97,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Total Non-Operating Income/Expense | (272.93M) | (257.68M) | (311.87M) | (496.08M) | (562.93M) | [{"date":"2020-12-31","value":-27293300000,"profit":false},{"date":"2021-12-31","value":-25767500000,"profit":false},{"date":"2022-12-31","value":-31186700000,"profit":false},{"date":"2023-12-31","value":-49607800000,"profit":false},{"date":"2024-12-31","value":-56293400000,"profit":false}] |
| Pre-Tax Income | (35.78M) | 31.37M | (248.13M) | (40.27M) | (55.01M) | [{"date":"2020-12-31","value":-114.07,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-791.07,"profit":false},{"date":"2023-12-31","value":-128.39,"profit":false},{"date":"2024-12-31","value":-175.39,"profit":false}] |
| Income Taxes | (104.36M) | 11.20M | 6.66M | 8.45M | 18.86M | [{"date":"2020-12-31","value":-553.24,"profit":false},{"date":"2021-12-31","value":59.35,"profit":true},{"date":"2022-12-31","value":35.32,"profit":true},{"date":"2023-12-31","value":44.81,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Income After Taxes | 68.58M | 20.17M | (254.79M) | (48.72M) | (73.88M) | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":29.41,"profit":true},{"date":"2022-12-31","value":-371.53,"profit":false},{"date":"2023-12-31","value":-71.05,"profit":false},{"date":"2024-12-31","value":-107.73,"profit":false}] |
| Income From Continuous Operations | 68.58M | 20.17M | (254.79M) | (48.72M) | (73.88M) | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":29.41,"profit":true},{"date":"2022-12-31","value":-371.53,"profit":false},{"date":"2023-12-31","value":-71.05,"profit":false},{"date":"2024-12-31","value":-107.73,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | 91.06M | 10.62M | (129.99M) | (83.99M) | (116.89M) | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":11.67,"profit":true},{"date":"2022-12-31","value":-142.75,"profit":false},{"date":"2023-12-31","value":-92.24,"profit":false},{"date":"2024-12-31","value":-128.36,"profit":false}] |
| EPS (Diluted) | 0.63 | 0.84 | 0.68 | 0.64 | 0.58 | [{"date":"2020-12-31","value":75,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":80.95,"profit":true},{"date":"2023-12-31","value":76.19,"profit":true},{"date":"2024-12-31","value":69.05,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| AMRX | |
|---|---|
| Cash Ratio | 0.23 |
| Current Ratio | 2.13 |
| Quick Ratio | 1.42 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| AMRX | |
|---|---|
| ROA (LTM) | 6.79% |
| ROE (LTM) | -881.26% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| AMRX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 1.03 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.03 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| AMRX | |
|---|---|
| Trailing PE | 1519.00 |
| Forward PE | 6.30 |
| P/S (TTM) | 1.63 |
| P/B | 86.10 |
| Price/FCF | 46 |
| EV/R | 2.43 |
| EV/Ebitda | 12.86 |
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) share price today is $14.85
Yes, Indians can buy shares of Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) on Vested. To buy
Yes, you can purchase fractional shares of Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) via the Vested app. You can start investing in Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) with a minimum investment of $1.
You can invest in shares of Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) via Vested in three simple steps:
The 52-week high price of Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is $15.42. The 52-week low price of Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is $6.68.
The price-to-earnings (P/E) ratio of Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is 1482
The price-to-book (P/B) ratio of Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is 86.10
The dividend yield of Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is 0.00%
The market capitalization of Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is $4.78B
The stock symbol (or ticker) of Amneal Pharmaceuticals, Inc. Class A Common Stock is AMRX
Consider the share price of Amneal Pharmaceuticals, Inc. Class A Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Amneal Pharmaceuticals, Inc. Class A Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Amneal Pharmaceuticals, Inc. Class A Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Amneal Pharmaceuticals, Inc. Class A Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Amneal Pharmaceuticals, Inc. Class A Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Amneal Pharmaceuticals, Inc. Class A Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
